Dermira Inc. (NASDAQ:DERM)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a report issued on Wednesday.

Other research analysts also recently issued reports about the stock. Leerink Swann reiterated a “buy” rating and issued a $47.00 price target (up from $46.00) on shares of Dermira in a research report on Thursday, June 2nd. Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. Finally, Wedbush raised their price objective on shares of Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a research report on Thursday, June 2nd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $41.00.

Shares of Dermira (NASDAQ:DERM) opened at 35.57 on Wednesday. Dermira has a 52-week low of $17.42 and a 52-week high of $36.16. The firm’s 50-day moving average is $32.35 and its 200 day moving average is $28.45. The stock’s market capitalization is $1.26 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/dermira-inc-derm-given-buy-rating-at-needham-company-llc.html

Dermira (NASDAQ:DERM) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by $0.03. Equities analysts expect that Dermira will post ($3.39) EPS for the current year.

In other news, insider Luis C. Pena sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 23rd. The shares were sold at an average price of $30.01, for a total transaction of $300,100.00. Following the sale, the insider now directly owns 14,653 shares in the company, valued at approximately $439,736.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Christopher M. Griffith sold 1,303 shares of the firm’s stock in a transaction on Friday, July 15th. The shares were sold at an average price of $30.02, for a total transaction of $39,116.06. Following the sale, the vice president now owns 44,941 shares in the company, valued at $1,349,128.82. The disclosure for this sale can be found here. Insiders own 17.30% of the company’s stock.

Several hedge funds have recently made changes to their positions in DERM. Schwab Charles Investment Management Inc. increased its stake in shares of Dermira by 30.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 62,986 shares of the biopharmaceutical company’s stock valued at $1,843,000 after buying an additional 14,566 shares during the last quarter. American Century Companies Inc. purchased a new stake in shares of Dermira during the second quarter valued at approximately $1,352,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Dermira by 25.5% in the second quarter. Metropolitan Life Insurance Co. NY now owns 15,819 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 3,210 shares during the last quarter. Point72 Asset Management L.P. increased its stake in shares of Dermira by 66.5% in the second quarter. Point72 Asset Management L.P. now owns 127,700 shares of the biopharmaceutical company’s stock valued at $3,735,000 after buying an additional 51,000 shares during the last quarter. Finally, Iguana Healthcare Management LLC increased its stake in shares of Dermira by 172.7% in the second quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biopharmaceutical company’s stock valued at $4,388,000 after buying an additional 95,000 shares during the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Dermira Company Profile

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

5 Day Chart for NASDAQ:DERM

Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.